School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa.
School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits, Johannesburg 2050, South Africa.
Anticancer Agents Med Chem. 2021;21(10):1228-1239. doi: 10.2174/1871520620666200929153138.
The persistence of breast cancer as the leading cause of mortality among women, coupled with drug resistance to tamoxifen, the standard endocrine therapy for the disease, exacts continuous attention. To this effect, molecular hybridisation offers an attractive route to drugs with improved bioactivity profiles.
The primary goal of this study was to examine the potential of 1H-1,2,3-triazole linked quinolineisatin molecular hybrids as drug candidates against breast cancer and Methicillin-Resistant Staphylococcus aureus (MRSA) cells.
The quinoline-isatin hybrids were synthesised via click chemistry-mediated molecular hybridisation strategy. Anti-breast cancer activity was determined in 3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using Estrogen-Responsive (ER+) MCF-7 and MDA-MB-231 (Triple-Negative Breast Cancer -TNBC) cells, while antimicrobial efficacy was established via the broth dilution method. Also, the toxicity profile of potent compounds to non-cancerous cells was determined using human embryonic kidney cells (HEK293) and human Red Blood Cells (hRBCs). In silico techniques were employed to predict the druglike properties of potent compounds and understand their binding modes with Estrogen Receptor alpha (ERα).
Compounds 7g-i exhibited the strongest cytotoxicity to MCF-7 cells with IC values of 23.54, 23.66, and 32.50μM, respectively. Interestingly, compound 7h also emerged as the best drug candidate against MDAMB- 231 and MRSA cells with IC=71.40μM and MIC=27.34μM, respectively. Structure-activity relationship analysis revealed that quinoline-2-carbaldehyde and 5,7-disubstituted isatin moieties confer desirable potency. These compounds showed no significant cytotoxic or haemolytic effects on HEK293 or hRBCs in vitro at their active concentrations; hence, eliciting their selectivity for cancer cells. In silico studies also presented the drugability of potent compounds and the likely structural features interacting with amino acid residues at the ligandbinding domain of ERα.
These results suggest that the identified 1H-1,2,3-triazole-linked quinoline-isatin hybrids are viable chemotypes that can be adopted as templates for the development of new anti-breast cancer and anti-MRSA agents.
乳腺癌仍然是女性死亡的主要原因,而且对他莫昔芬(用于治疗乳腺癌的标准内分泌疗法)产生耐药性,这需要持续关注。为此,分子杂交为具有改善的生物活性谱的药物提供了一条有吸引力的途径。
本研究的主要目的是研究 1H-1,2,3-三唑连接的喹啉异吲哚分子杂化物作为针对乳腺癌和耐甲氧西林金黄色葡萄球菌(MRSA)细胞的候选药物的潜力。
通过点击化学介导的分子杂交策略合成了喹啉-异吲哚杂化物。使用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴盐(MTT)测定法在雌激素反应性(ER+)MCF-7 和 MDA-MB-231(三阴性乳腺癌-TNBC)细胞中测定抗乳腺癌活性,而通过肉汤稀释法确定抗菌功效。还用人胚胎肾细胞(HEK293)和人红细胞(hRBC)测定了潜在化合物对非癌细胞的毒性谱。采用计算技术预测潜在化合物的类药性并了解它们与雌激素受体 alpha(ERα)的结合模式。
化合物 7g-i 对 MCF-7 细胞的细胞毒性最强,IC 值分别为 23.54、23.66 和 32.50μM。有趣的是,化合物 7h 也是针对 MDAMB-231 和 MRSA 细胞的最佳候选药物,IC=71.40μM 和 MIC=27.34μM。构效关系分析表明,喹啉-2-醛和 5,7-二取代异吲哚部分赋予了所需的效力。这些化合物在其活性浓度下在体外对 HEK293 或 hRBC 没有明显的细胞毒性或溶血作用;因此,它们对癌细胞具有选择性。计算研究还展示了潜在化合物的可药性以及与 ERα 配体结合域中的氨基酸残基相互作用的可能结构特征。
这些结果表明,鉴定出的 1H-1,2,3-三唑连接的喹啉-异吲哚杂化物是可行的化学型,可以作为开发新的抗乳腺癌和抗 MRSA 药物的模板。